Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001346467 | SCV001540674 | uncertain significance | Focal segmental glomerulosclerosis 5; Charcot-Marie-Tooth disease dominant intermediate E | 2020-05-12 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with INF2-related conditions. This variant is present in population databases (rs770095888, ExAC 0.003%). This sequence change replaces alanine with glycine at codon 1041 of the INF2 protein (p.Ala1041Gly). The alanine residue is weakly conserved and there is a small physicochemical difference between alanine and glycine. |
Fulgent Genetics, |
RCV001346467 | SCV002793053 | uncertain significance | Focal segmental glomerulosclerosis 5; Charcot-Marie-Tooth disease dominant intermediate E | 2022-04-26 | criteria provided, single submitter | clinical testing |